Asuragen subsidiary Mirna Therapeutics this week unveiled preclinical data showing that one of its microRNA mimics inhibited tumor growth and metastases in a variety of animal models without toxicity.

These data, along with the publication last week of a report showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, suggest that miRNA replacement could be a safe and effective therapeutic strategy for cancer, Mirna CEO Matt Winkler told RNAi News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.